XENE
Xenon Pharmaceuticals Inc.
Company Overview
| Mkt Cap | $4.84B | Price | $57.65 |
| Volume | 667.64K | Change | +0.00% |
| P/E Ratio | -20.6 | Open | $56.69 |
| Revenue | -- | Prev Close | $57.65 |
| Net Income | $-234.3M | 52W Range | $26.74 - $63.95 |
| Div Yield | N/A | Target | $79.05 |
| Overall | 63 | Value | -- |
| Quality | -- | Technical | 63 |
No chart data available
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Latest News
Xenon to Unveil Phase 3 Azetukalner Data and Pipeline Advances at 2026 AAN Meeting
H.C. Wainwright Keeps Their Buy Rating on Xenon (XENE)
Xenon’s X-TOLE2 Trial Completion Puts XEN1101 in Focus for Epilepsy Investors
Bank of America Securities Keeps Their Buy Rating on Xenon (XENE)
Xenon Raises $650 Million in Upsized U.S. Equity Offering
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | XENE | $57.65 | 0% | 667.64K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Xenon Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW